|
Colorectal Carcinoma
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
NKp46-expressing human gut-resident intraepithelial Vδ1 T cell subpopulation exhibits high anti-tumor activity against colorectal cancer.
|
31689241 |
2019 |
|
Colorectal Carcinoma
|
0.310 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Despite a large body of evidence highlighting its importance in the clearance of both solid and liquid tumors, the membrane-bound tumor ligand for NKp46 and its mouse orthologue Ncr1 is still unknown.
|
31606778 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Natural killer group 2D (NKG2D) is a natural killer (NK) cell-activating receptor that recognizes different stress-induced ligands that are overexpressed in a variety of childhood and adult tumors.
|
31649672 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We observe the downregulation of several activation receptors including CD16, CD62L, C-X-C chemokine receptor (CXCR)-4, natural killer group 2 member D (NKG2D), DNAX accessory molecule (DNAM)-1, and NKp46 following tumor-priming.
|
31242243 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, we demonstrated that blocking NKp46 receptor <i>in vitro</i> was able to restore spontaneous tumor specific T cell responses in NSCLC patients.
|
30713781 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although LILRB1 was detected regardless of the disease entity, the activating NK-cell receptors were expressed predominantly in TIA-1-positive neoplasms (DNAM1, 49%; NKp46, 69%; and NKG2D, 38%).
|
29363227 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As a result, NKGD2-deficient (Klrk1<sup>-/-</sup>) mice controlled tumors and cytomegalovirus infection better than wild-type controls through the NCR1-induced production of the cytokine IFN-γ.
|
30224819 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Ly5.1<sup>C14R</sup> NK cells expressed similar levels of <i>Ncr1</i> mRNA as C57BL/6, but showed impaired surface NKp46 and reduced ability to control melanoma tumors <i>in vivo</i>.
|
30288342 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The natural cytotoxicity receptors (NCRs; NKp30, NKp44, and NKp46) were first defined as activating receptors on human NK cells that are important in recognition of and response to tumors.
|
29264698 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Injection of IFN-γ into tumor-bearing mice or transgenic overexpression of Ncr1 in NK cells in mice resulted in decreased metastasis formation.
|
29329948 |
2018 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Co-regulatory networks of human serum proteins link genetics to disease.
|
30072576 |
2018 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomic atlas of the human plasma proteome.
|
29875488 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
NKp46/Ncr1 also recognizes unknown self and tumor ligands.
|
29026144 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Enumeration of the tumor microenvironment cell population was undertaken using in silico analysis of the transcriptional data, and real-time PCR validation of NCR1 undertaken.
|
28621318 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hpsefl/fl NKp46-iCre mice were also more susceptible to tumor growth than were their littermate controls when challenged with the established mouse lymphoma cell line RMA-S-RAE-1β, which overexpresses the NK cell group 2D (NKG2D) ligand RAE-1β, or when inoculated with metastatic melanoma, prostate carcinoma, or mammary carcinoma cell lines.
|
28581441 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using several mouse tumor models, we demonstrate the importance of NK cells in protection from reovirus infection and in reovirus killing of tumors <i>in vivo</i> Collectively, we identify a new ligand for the NKp46 receptor and provide evidence for the importance of NKp46 in the control of reovirus infections and in reovirus-based cancer therapy.
|
28724773 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cases did not show differences in NKp46 demethylation based on tumor site or stage.
|
23014525 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The mechanisms controlling the recognition of tumor- and virus-infected cells by NKp46.
|
14504081 |
2004 |
|
Influenza
|
0.050 |
Biomarker
|
disease |
BEFREE |
In contrast, loss of NCR1 increased susceptibility to influenza virus, a result that is consistent with the role of NCR1 in the recognition of influenza Ag, hemagglutinin.
|
29440507 |
2018 |
|
Influenza
|
0.050 |
Biomarker
|
disease |
BEFREE |
The influenza virus hemagglutinin (HA) was the first ligand identified for Ncr1/NKp46 followed by other viral, bacterial and even fungal ligands.
|
29026144 |
2017 |
|
Influenza
|
0.050 |
Biomarker
|
disease |
BEFREE |
The only definitive ligand of NCR1 is influenza haemagglutinin, though there are believed to be others.
|
22212381 |
2012 |
|
Influenza
|
0.050 |
Biomarker
|
disease |
BEFREE |
There was enhanced spread of certain tumors in 129/Sv but not C57BL/6 Ncr1(gfp/gfp) mice, and influenza virus infection was lethal in both 129/Sv and C57BL/6 Ncr1(gfp/gfp) mice.
|
16565719 |
2006 |
|
Influenza
|
0.050 |
Biomarker
|
disease |
BEFREE |
Recently, we have identified a novel functional interaction between the lysis receptors NKp46 and NKp44 and the hemagglutinin of influenza and hemagglutinin-neuroaminidase of Sendai viruses.
|
14504081 |
2004 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Most importantly, we showed that a toxin-conjugated 02 inhibits the growth of NKp46-positive cells; thus, exemplifying the potential of 02 in becoming an immunotherapeutic drug to treat NKp46-dependent diseases, such as, type I diabetes and NK and T cell related malignancies.
|
30536875 |
2019 |